1. Home
  2. EOLS vs NIE Comparison

EOLS vs NIE Comparison

Compare EOLS & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
    SELLHOLDBUYas of a day ago
  • NIE
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • EOLS 2012
  • NIE 2007
  • Country
  • EOLS United States
  • NIE United States
  • Employees
  • EOLS N/A
  • NIE N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • NIE Investment Managers
  • Sector
  • EOLS Health Care
  • NIE Finance
  • Exchange
  • EOLS Nasdaq
  • NIE Nasdaq
  • Market Cap
  • EOLS 854.0M
  • NIE 697.4M
  • IPO Year
  • EOLS 2018
  • NIE N/A
  • Fundamental
  • Price
  • EOLS $12.05
  • NIE $22.19
  • Analyst Decision
  • EOLS Strong Buy
  • NIE
  • Analyst Count
  • EOLS 4
  • NIE 0
  • Target Price
  • EOLS $24.67
  • NIE N/A
  • AVG Volume (30 Days)
  • EOLS 748.3K
  • NIE 70.5K
  • Earning Date
  • EOLS 03-04-2025
  • NIE 01-01-0001
  • Dividend Yield
  • EOLS N/A
  • NIE 9.04%
  • EPS Growth
  • EOLS N/A
  • NIE N/A
  • EPS
  • EOLS N/A
  • NIE N/A
  • Revenue
  • EOLS $266,274,000.00
  • NIE N/A
  • Revenue This Year
  • EOLS $34.56
  • NIE N/A
  • Revenue Next Year
  • EOLS $32.26
  • NIE N/A
  • P/E Ratio
  • EOLS N/A
  • NIE N/A
  • Revenue Growth
  • EOLS 31.76
  • NIE N/A
  • 52 Week Low
  • EOLS $9.25
  • NIE $18.61
  • 52 Week High
  • EOLS $17.82
  • NIE $22.47
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 35.35
  • NIE 36.67
  • Support Level
  • EOLS $13.07
  • NIE $22.22
  • Resistance Level
  • EOLS $13.66
  • NIE $22.86
  • Average True Range (ATR)
  • EOLS 0.58
  • NIE 0.42
  • MACD
  • EOLS -0.15
  • NIE 0.06
  • Stochastic Oscillator
  • EOLS 22.22
  • NIE 41.74

Stock Price Comparison Chart: EOLS vs NIE

EOLS
NIE
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober202505101520253035EOLS VS NIE

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use